Wanbury Q2 Results: Standalone Net Profit Drops to ₹1,188 Lakhs
Wanbury Ltd · Outcome · 05 Nov 2026, 2:25 am
Wanbury Q2 Results: Standalone Net Profit Drops to ₹1,188 Lakhs Wanbury reported Q2'26 standalone revenue from operations of ₹18,290.97 lakhs, up 14.3% YoY and 10.5% QoQ. Standalone PAT fell 21.7% YoY to ₹1,188.23 lakhs (₹1,518.03 lakhs in Q2'25), though it rebounded sharply from ₹324.29 lakhs in Q1'26. Consolidated Q2'26 revenue stood at ₹18,290.97 lakhs with PAT of ₹852.62 lakhs. During the quarter, Wanbury incorporated an 82%-owned subsidiary, Wanbury Skin Health Limited, entering the dermatology and baby care segments, which commenced operations in Oct'26 after incurring ₹335.60 lakhs in pre-operative expenses.
Original exchange filing (PDF)
More announcements from Wanbury Ltd
- Disclosure under Regulation 30 of the SEBI LODR, 2015 - Investors Presentation on Q2 and Half Year ended 30.09.2026. · 18 Nov 2026
- Clarifications on investor queries regarding recent announcement · 16 Nov 2026
- Wanbury Limited''s Tanuku Plant - US FDA Inspection - Updates · 16 Nov 2026
- Wanbury Limited received regulatory approval (CADIFA: Letter of suitability for API) from ANVISA (Brazil FDA) for its flagship product Metformin HC1 EP grade. · 12 Nov 2026
- Press Release on Standalone and Consolidated Un-audited Financial Results for the second quarter & half year ended 30th September, 2026. · 06 Nov 2026
- Financial Results as on 30th September, 2026 · 05 Nov 2026
- Outcome of the Board Meeting held on November 04, 2026 · 05 Nov 2026
- Wanbury Limited receives Australian TGA GMP Compliance Certificate for its Tanuku Plant, Strengthening Its Global Pharmaceutical Manufacturing Credentials. · 30 Oct 2026
